10% Owner Mohamad Makhzoumi Buys $15M in SpyGlass Pharma Stock Post-IPO

summarizeSummary

Mohamad Makhzoumi, a 10% owner affiliated with New Enterprise Associates, made a substantial $15 million open market purchase of SpyGlass Pharma common stock at the IPO price, alongside the automatic conversion of $169 million in preferred shares.

check_boxKey Events

• Significant Open Market Purchase

  Mohamad Makhzoumi, a 10% owner, purchased $15 million worth of common stock on the open market.

• Purchase at IPO Price

  The purchase was made at the IPO price of $16.00 per share on February 9, 2026, the same day the IPO closed.

• Large Preferred Stock Conversion

  Additionally, approximately $169 million in preferred stock automatically converted to common stock as part of the IPO, solidifying a substantial institutional holding.

• Part of Broader Insider Accumulation

  This transaction follows a series of significant insider purchases by other directors and 10% owners post-IPO, indicating a strong cluster buying signal.

auto_awesomeAnalysis

This filing highlights a significant vote of confidence from a major institutional investor, Mohamad Makhzoumi, a 10% owner associated with New Enterprise Associates. The $15 million open market purchase, executed at the IPO price of $16.00 per share, represents a substantial investment following the company's recent public debut. This discretionary purchase, combined with the automatic conversion of approximately $169 million in preferred stock to common stock, solidifies a massive stake in SpyGlass Pharma. This transaction is part of a broader pattern of strong insider accumulation post-IPO, with multiple directors also making significant purchases, signaling robust internal conviction in the company's future prospects.